Early Phase III data from Pfizer and BioNTech BNT162b2 is the experimental mRNA-based vaccine candidate from Pfizer and BioNTech’s in Phase III study. Since June, 43,538 participants have been enrolled to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8. On Monday, November 9th, the company announced […]
Tagged: mRNA-based vaccine candidate
Closer to a COVID-19 vaccine with over 90% effectiveness
November 11th, 2020 | mRNA-based vaccine candidateCategories
- Biomarkers & Surrogate Endpoints
- Company News
- Drug Development
- Due Diligence
- Early Clinical Development
- Industry News
- Medical Affairs and Clinical Research
- Miscellaneous
- Orphan Diseases
- Pre-IND
- Precision Medicine
- Rare Disease
- Real World Evidence
- Regulatory
- Regulatory Affairs
- Strategy and TPP
- Translation Medicine and Epigenetics
- Trial Management
- Trial Rescue
Recent Posts
- Dr. Candida Fratazzi is a pioneering figure in the area of rare diseases and orphan drug early-stage clinical research and regulatory strategies. With an impressive 20-year track record in this specialized field, Dr. Fratazzi’s contributions have been significant.
- BBCR is dedicated to supporting pharmaceutical innovators in the specialized rare diseases and orphan drug indications by developing and nurturing the product’s unique strengths. Our operational mission is to craft customized strategies that achieve cost-effective trials. Reach out today to learn more.
- BBCR provides Orphan Drug solutions that empower sponsors with medical insight, ODA application experience, strategic clinical planning, and streamlined trial design.
- By collaborating with Boston Biotech Clinical Research, you’ll be working with a team of experts who are dedicated to streamlining the clinical trial process.
- BBCR’s mission is to deliver cost-effective clinical plans and regulatory strategies for cell and gene therapy programs in the areas of rare disease. We invite you to learn more at bbcrconsulting.com.